| P2093 | author name string | Minnie M Sarwal | |
| | Manpreet Singh | |
| | Yolanda W Ng | |
| P2860 | cites work | Protein microarrays discover angiotensinogen and PRKRIP1 as novel targets for autoantibodies in chronic renal disease | Q24320230 |
| | Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. | Q53924174 |
| | Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. | Q55034268 |
| | The Role of Toll‐Like Receptors in Herpes Simplex Infection in Neonates | Q57636327 |
| | Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab | Q57903178 |
| | Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA–Incompatible Kidney Transplantation | Q58048136 |
| | Posttransplant Soluble B-Cell Activating Factor Kinetics in Pediatric Recipients of First Kidney Allograft | Q58620392 |
| | The Banff 97 working classification of renal allograft pathology | Q59314413 |
| | Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab | Q61716538 |
| | The vascular endothelial cell antigen system | Q69939809 |
| | Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology | Q71111053 |
| | Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations | Q73138493 |
| | Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells | Q74317809 |
| | Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss | Q80225059 |
| | Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 |
| | Campath and renal transplant rejection | Q80935782 |
| | Non-HLA antibodies after rejection of HLA identical kidney transplants | Q80952235 |
| | Antibodies against MICA antigens and kidney-transplant rejection | Q81357717 |
| | Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies | Q81706493 |
| | Campath-1H use in pediatric renal transplantation | Q81737693 |
| | A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation | Q82026577 |
| | Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients | Q82588311 |
| | Acute antibody-mediated rejection in paediatric renal transplant recipients | Q83774038 |
| | Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies | Q84581805 |
| | Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 |
| | De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection | Q85846370 |
| | The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes | Q86635362 |
| | Histopathologic features of transplant glomerulopathy associated with response to therapy with intravenous immune globulin and rituximab | Q87378832 |
| | Significance of C1q-fixing donor-specific antibodies after kidney transplantation | Q87491598 |
| | Protective immunity and use of bortezomib for antibody-mediated rejection in a pediatric kidney transplant recipient | Q87665378 |
| | Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients | Q87763662 |
| | Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 |
| | Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ | Q46321287 |
| | Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. | Q46367397 |
| | Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen | Q46402292 |
| | Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients | Q46554252 |
| | Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch | Q46612734 |
| | Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection | Q46913121 |
| | Significance of the positive crossmatch test in kidney transplantation | Q47800073 |
| | Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 |
| | Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? | Q47880758 |
| | Phenotypic evaluation of B-cell subsets after rituximab for treatment of acute renal allograft rejection in pediatric recipients. | Q51016846 |
| | Reference values for B cell subpopulations from infancy to adulthood | Q51036853 |
| | Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. | Q51333222 |
| | Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. | Q51736686 |
| | Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. | Q53060554 |
| | The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 |
| | Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation | Q28655545 |
| | Introduction and overview of therapeutic apheresis | Q30451703 |
| | Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 |
| | A summary of bortezomib use in transplantation across 29 centers | Q33389915 |
| | The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation | Q33392607 |
| | Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report | Q33395870 |
| | Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts | Q33415390 |
| | Use of bortezomib as anti-humoral therapy in kidney transplantation | Q33627580 |
| | T-cell function in newborn mice and humans | Q33667803 |
| | Differentially Expressed RNA from Public Microarray Data Identifies Serum Protein Biomarkers for Cross-Organ Transplant Rejection and Other Conditions | Q33707373 |
| | Maturation of innate responses to mycobacteria over the first nine months of life | Q33723428 |
| | Gene-expression profiling for rejection surveillance after cardiac transplantation | Q34111639 |
| | Cytokine regulation of immunoglobulin secretion by neonatal lymphocytes | Q34199215 |
| | Neonatal and early life vaccinology | Q34248891 |
| | Development of interleukin-12-producing capacity throughout childhood | Q34259946 |
| | Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. | Q34260097 |
| | International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology | Q34354852 |
| | The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study | Q34489123 |
| | Clinicopathologic characteristics of post-transplant lymphoproliferative disorders. | Q34489650 |
| | Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. | Q35027253 |
| | Bortezomib for acute antibody-mediated rejection in liver transplantation | Q35538969 |
| | Endothelial cell antibodies associated with novel targets and increased rejection | Q35550551 |
| | Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin | Q35664634 |
| | Immune profile of pediatric renal transplant recipients following alemtuzumab induction | Q35720801 |
| | Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients | Q35730607 |
| | Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection | Q36078696 |
| | Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantation | Q36281955 |
| | The clinical impact of humoral immunity in pediatric renal transplantation. | Q36719246 |
| | The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection | Q36772871 |
| | Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection | Q36843420 |
| | Complete steroid avoidance is effective and safe in children with renal transplants: a multicenter randomized trial with three-year follow-up | Q36926228 |
| | Relevance of MICA and other non-HLA antibodies in clinical transplantation | Q37233488 |
| | A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation | Q37246506 |
| | Age related differences in dynamics of specific memory B cell populations after clinical pertussis infection | Q37472929 |
| | Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection | Q37654098 |
| | Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. | Q37989270 |
| | The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. | Q38023468 |
| | The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature | Q38063607 |
| | Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients | Q38117179 |
| | Biomarkers of tolerance. | Q38120394 |
| | An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts | Q38210431 |
| | A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection | Q38228333 |
| | Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant | Q38237202 |
| | Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes | Q39712114 |
| | Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. | Q39716270 |
| | Vascular endothelial alloantigens in renal transplantation | Q39826164 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells | Q40633802 |
| | The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics | Q41926369 |
| | Pretransplant Epstein-Barr virus serostatus and incidence of posttransplant lymphoproliferative disorder in pediatric renal transplants. | Q42279824 |
| | Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience | Q42280145 |
| | Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients | Q42656427 |
| | A peripheral blood diagnostic test for acute rejection in renal transplantation. | Q42848519 |
| | Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access | Q42968367 |
| | Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports. | Q43044466 |
| | Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report | Q43079825 |
| | Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 |
| | HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss | Q43288501 |
| | Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure | Q43918875 |
| | A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection | Q44197767 |
| | The endotoxin-induced increase of cytokines is followed by an increase of cortisol relative to dehydroepiandrosterone (DHEA) in healthy male subjects | Q44214400 |
| | Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells | Q44368031 |
| | Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection | Q44469234 |
| | The effects of androstenediol and dehydroepiandrosterone on the immune response to BCG at puberty | Q44504717 |
| | Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). | Q44514934 |
| | Antibody-mediated rejection and treatment in pediatric patients: one center's experience. | Q44519214 |
| | Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. | Q44533720 |
| | Rituximab as treatment for refractory kidney transplant rejection | Q44899030 |
| | Refined characterization and reference values of the pediatric T- and B-cell compartments | Q45191073 |
| | Impact of rituximab therapy for treatment of acute humoral rejection | Q45361905 |
| | Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation | Q45407225 |
| | A common blood gene assay predates clinical and histological rejection in kidney and heart allografts | Q45701579 |
| | Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody | Q45736192 |
| | Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression | Q45746648 |
| | Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection. | Q45821566 |
| | Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: an international prospective study (INTERCOM). | Q45898843 |
| | Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. | Q46007205 |
| | Operational tolerance in kidney transplantation-improved terminology may enable more precise investigation. | Q46023490 |
| | Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 |
| P433 | issue | 5 | |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 455-472 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Antibody-mediated rejection in pediatric kidney transplantation: pathophysiology, diagnosis, and management | |
| P478 | volume | 75 | |